Meeting
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
Authors
Hyojin Kim
Department of Pathology, Seoul National University Bundang Hospital, Seongnam, South Korea
Hyojin Kim , Sangjoon Choi , Seokhwi Kim , Jaehong Aum , Sergio Pereira , Seonwook Park , Minuk Ma , Seunghwan Shin , Kyunghyun Paeng , Donggeun Yoo , Wonkyung Jung , Chan-Young Ock , Se-Hoon Lee , Jin-haeng Chung , Yoon-La Choi , Tony S. K. Mok
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9026)
DOI
10.1200/JCO.2021.39.15_suppl.9026
Abstract #
9026
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Genomic correlates of acquired resistance to PD-(L)1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Biagio Ricciuti
Poster
2023 ASCO Breakthrough
Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
First Author: Stephanie Pei Li Saw
Poster
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
First Author: Huangbin Lu
Poster
2022 ASCO Annual Meeting
Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer.
First Author: Seokhwi Kim